Overactive Bladder: “Pharmacia instrumental in creating new disease” says Former VP
I just received a link to an old Powerpoint (PPT) presentation that was featured at an October, 2002, Pharmaceutical Marketing Research Group (PMRG) conference....
FDA’s Actions Speak Louder than Its Words: On the Internet It’s the Medium as...
It has been widely reported that as far as the FDA is concerned it's the message not the medium when it comes to regulating...
Detrol v. Toviaz: Marketing Replaces Innovation at Pfizer!
"You won't have bathroom lady to kick around anymore because, gentlemen, this is my last DTC appearance," said the iconic Detrol spokesperson.Yes, Detrol is...
Should FDA Convene a Public Hearing on Use of Social Media by Pharma?
Now that everybody has calmed down about my April Fools joke (ie, "FDA Issues First-ever Draft Guidance on Pharma’s Use of Social Media!"), we...
FDA and Pharma – Bring More Stakeholders into Your Discussion of Social Media Guidelines!...
If you were taken in by my FDA-social media guidance April Fool's post (see here), you were not alone. Many other savvy people were...
FDA Issues First-ever Draft Guidance on Pharma’s Use of Social Media!
The US Food and Drug Administration (FDA) today issued a new guidance document that addresses the use of “social media” by pharmaceutical companies.I'm very...
Report from the Social Pharmer “Unconference”: Sowing Seeds of Social Media Change?
This article summarizes key presentations made at the April 21, 2009, Social Pharmer 'unconference' where leading pahram social media proponents presnted ideas on how the industry can overcome the barriers.
Socially Challenged Pharma: How Ready is Pharma to Engage In Social Media?
This article summarizes the recent Digital Pharma Europe congress where it was the time right to see that European pharma marketers are also interested in new/social/digital media in pharma, but may be more constrained by regulators than their brethern in the US.
The Empowered Patient: What It Means for Pharma Marketers
This article presents a case for the drug industry to adopt a patient-centric model in which pharma companies can develop unique expertise in decoding the behavior, needs, motivations of empowered patients and then use this knowledge as the basis for helping healthcare professionals and payers to put into place programs that achieve better patient outcomes.
Developing Guidelines for Pharma’s Use of the Internet & Social Media: Whatever! A Call...
Shouldn't we make sure that when it comes time for the FDA to actually create a guidance document on social media that it does it with input from ALL stakeholders? Survey results.
